Our Latest Weekly Report is out — read, reflect, and share your thoughts in the comments. What’s Inside This Report? · Market Outlook: Fed Hikes, BOJ Hikes, Nifty Holds — Rally Attempt Begins · Learning Article: 8% Down, Not Out · Featured Article: The Exchange That Can't List Itself · Idea Lists: Five Stocks to Watch Right Now This report highlights the key themes shaping markets and investment opportunities, with the Market Outlook: Fed Hikes, BOJ Hikes, Nifty Holds — Rally Attempt Begins examining how the Nifty defended key support despite hawkish moves from two major central banks, volatile crude prices, and weak sector breadth, allowing the market to shift from a Downtrend to a Rally Attempt. Learning Article: 8% Down, Not Out explains how disciplined loss-cutting at 7–8% can help protect capital and prevent a manageable mistake from becoming a damaging portfolio loss. In the Featured Article: The Exchange That Can't List Itself, we examine the unique story behind NSE’s public listing on rival BSE and what the event reveals about market structure, liquidity, valuation, shareholder dynamics, and India’s exchange ecosystem. Finally, Idea Lists: Five Stocks to Watch Right Now features breakout candidates exhibiting strong relative strength, institutional accumulation, and promising technical setups near key pivot levels. Read the full report here: zurl.co/lmpaS #MarketSmithIndia #WeeklyReport #ONeilMethodology #StockMarketIndia #Investing #Trading #GrowthStocks #PortfolioStrategy #IndianEquities #SmartInvesting

NephroPlus — revenue up 23.7%, and it splits almost exactly into treatments and price per treatment. Q1 FY27, from the investor call (12 Aug 2026): Revenue Rs 282 cr, against Rs 228 cr Treatments 10.3 lakh, up 13.3% Revenue per treatment Rs 2,733, up 9.2% Active patients 38,262, up 13% Adjusted EBITDA Rs 65.1 cr, a 23.1% margin Adjusted PAT Rs 37 cr, up 41.7% 550 clinics, 357 cities, 5 countries The decomposition: 1.133 times 1.092 is 1.237. Volume and realisation explain the whole top line. The realisation leg is mix, not pricing. International operations are now about 45% of revenue, and realisations there are higher than in India. The Philippines crossed 50 clinics, and Uzbekistan serves about 1,800 of roughly 9,000 patients. The tension is physics. Per the founder, a machine can do only three cycles a day, and network utilisation is 74%. Growth past that point needs new clinics, which means capex.

LG Electronics India — a Rs 5,000 cr plant, Rs 5,707 cr of cash, and no borrowing to pay for it. Q1 FY27, from the earnings call: Revenue Rs 7,233 cr, up 15.5% EBITDA Rs 944 cr, a 12.5% margin, up 110 bps PAT Rs 653 cr, up 27% Home entertainment revenue up 22%; segment margin 19% 55-inch-plus TVs are now about half the TV business Exports up 30%, to 65 countries (45–47 at the IPO) The capex arithmetic: Sri City in Andhra Pradesh is a Rs 5,000 cr investment. Compressor production starts in Q3 FY27 and room ACs in Q4 FY27. Management says the plant nearly doubles manufacturing capacity, funded from internal accruals against a cash balance of Rs 5,707 cr. Localisation is at 55.2% against a 65% target over three to four years. Each point cut is import and currency exposure removed. The tension: management flags near-term plant ramp-up costs from H2 FY27. The compressor import restrictions of 8 May help local makers, but they could push import-dependent rivals into aggressive pricing.

The market still sees a winding-wire company riding copper prices. But beneath the headline growth, a second engine is quietly taking shape—copper tubes, import substitution and a deeper play on India’s electrification and cooling boom. The real test? Whether the new mix can finally change the economics. Read more: zurl.co/Bk8aV #RamRatnaWires #Copper #Electrification #PowerSector #Manufacturing #ImportSubstitution #IndianStocks #CapitalGoods #GrowthInvesting #MarketSmithIndia

Moneyview — Rs 22,520 cr of loans on the platform, and only a quarter of it sits on its own book. From the RHP, as of 30 Jun 2026: Managed AUM Rs 22,520 cr, up from Rs 17,708 cr a year earlier On-book (its NBFC, WFLP) Rs 5,657 cr Off-book, serviced for partners, Rs 16,863 cr FY26 loan disbursals Rs 23,099 cr, up 31% Q1 FY27 disbursals Rs 7,152 cr, against Rs 5,099 cr 22 regulated lending entities on the platform The concentration maths: on the Rs 5,657 cr book, the company carries all of the credit risk. On the partner loans, the default loss guarantee is capped at 5%. The RHP puts DLG outstanding at 43.92% of net worth. The partner side is concentrated too: the top 10 partners make up 37.36% of revenue. The tension: FY26 total income rose to Rs 3,404 cr from Rs 2,379 cr, while PAT barely moved (Rs 243 cr against Rs 240 cr). Rs 325 cr of the fresh issue goes to growing DLG-backed disbursals, which means more guaranteed exposure, not less.

South Indian Bank — profit up 17%, operating profit down 12%. Provisions did the work. Q1 FY27, from the investor presentation: NII Rs 1,025 cr, up 23%, the highest ever Non-interest income Rs 379 cr, against Rs 622 cr Treasury and forex income Rs 44 cr, against Rs 256 cr Operating profit Rs 592 cr, down 12% Provisions Rs 84 cr, against Rs 239 cr PAT Rs 378 cr, up 17% NIM 3.23%, up 20 bps Gross NPA 1.38%, against 3.15% Read the split: the core engine improved and the treasury line collapsed. The profit growth came from what the bank did not have to set aside. Gold loans are Rs 24,930 cr, up 43%, and now nearly a quarter of gross advances. The tension: management called the income drop 'an aberration', while Q1 credit cost of 9 bps is one it described as 'on a generous side'. Treasury income is the line that moves with bond yields, and yields are at multi-year highs globally.

Milky Mist — paneer is 26–27% of revenue, and organised players make only 5–7% of India's paneer. Q1 FY27, from the earnings call (1 Sep 2026): Revenue Rs 973 cr, up 44% YoY Gross margin 34.2%, up about 270 bps EBITDA Rs 145 cr, a 14.9% margin, against 12.2% a year ago PAT Rs 64.7 cr Paneer revenue Rs 248 cr; volume and value both up 34% Milk procured: 13.2 lakh litres a day, up 28% The unit economics: farmers are paid Rs 41–42 a litre and the landed cost is about Rs 45. Milk is 50–55% of input cost. Product prices went up about 10.5%, and gross margin still expanded. The market maths, per management: 90–95% of paneer is unorganised, and the company holds about 20% of the organised slice. The tension is the next cost round. Aavin has raised milk prices by Rs 3 twice, and management waits two to three months before repricing. Management also declined to commit to an 18% EBITDA margin, saying it may come in three to four years.

SEBI's new PMS rulebook: 70 pages cut to 33, provisos from 47 to 4. 215th SEBI Board meeting, 24 Sep. From press release PR 59/2026: Portfolio Managers Regulations, 2026 replace the 2020 rules New PRIM route: portfolio managers can run direct-plan mutual fund, ETF, index fund and SIF portfolios PRIM minimum ticket Rs 25 lakh, fixed fee capped at 1% of AUM, 25% cap on group-AMC schemes PMS allowed into IPOs and primary debt; up to 10% of AUM in investment-grade unlisted debt, with client consent Dealing-room norm relaxed for PMs under Rs 100 cr AUM, which covers 48% of registered PMs FPIs allowed into non-cash-settled non-agri commodity derivatives, with exit before the tender period Vault-manager net worth raised from Rs 50 cr to Rs 75 cr Settlement: fast track up to Rs 10 lakh; filing window after a show-cause notice extended from 60 to 90 days These are Board approvals. The rules apply only once notified, and the settlement regulations start on the 31st day after notification. The line to reread: distribution and PRIM clients must be kept separate, except for accredited investors. A managed direct-plan product runs into the distributor's business model. The second tension: foreign access is being widened in a month when FPIs have pulled out more than Rs23,000 cr. Which intermediaries gain share is not something the release answers. The notified text will.

The market sees MTAR as a proxy for one big customer. But the order book is quietly telling another story—fuel cells, nuclear, defence and data-centre infrastructure are beginning to converge on the same engineering platform. What if one customer was only the beginning? Read more: zurl.co/b1oTl #MTARTechnologies #CleanEnergy #NuclearEnergy #DefenceStocks #DataCenters #PrecisionEngineering #IndianStocks #MakeInIndia #GrowthInvesting #MarketSmithIndia

The market thought it was pricing an insurance distributor. Then one regulatory draft exposed a much bigger question: what happens when the rules change not just the payout—but the customer-acquisition engine itself? The real story is hidden in the fine print. Read more: zurl.co/HnzPU #PBFintech #Policybazaar #Insurance #Fintech #IndianStocks #IRDAI #DigitalFinance #StockMarketIndia #MarketTrends #MarketSmithIndia

IRDAI's draft wants to halve health renewal commissions. Policybazaar's core renewal and trail revenue is Rs 1,003 cr a year. What the consultation paper proposes (comments open till 25 Oct, effective from FY28): Pure-term first-year commission cap: 25% for banks, brokers and aggregators, 30% for agents, against an industry average of 51% New-business health: 15–20%, from more than 30% Health renewals: 5–10%, roughly halved Motor own damage: 5–10% New-vehicle motor third-party: 0–2.5% No phone number required just to see a quote PB Fintech, Q1 FY27: Core online premium Rs 5,760 cr Core insurance revenue Rs 1,070 cr, +46% Core renewal and trail revenue, 12-month rolling: Rs 1,003 cr, +38% The renewal line was the bull case: revenue that repeats without fresh marketing spend. It is also the line the draft cuts deepest. Two things cut the other way. This is a consultation, not a regulation. And the same paper lets intermediaries sell non-insurance services. No view here on the stock. The number to watch is the final health-renewal cap, not today's print.

Shaily Engineering grew 14%. That number hides a +85% and a -24%. Q1 FY27 investor presentation: Revenue Rs 280.7 cr, up 14% YoY EBITDA Rs 83.3 cr, margin 29.7% (+120 bps) PAT Rs 48.0 cr Now the split: Healthcare Rs 142.4 cr, +85% — about 51% of revenue, now the largest segment Consumer Rs 115.5 cr, -24% — softer home-furnishing demand in Europe and the US Industrial Rs 22.7 cr, +25% Two businesses moving in opposite directions, averaging into a headline that describes neither. The healthcare engine is injector pens: close to 90 lakh devices in Q1, 50–60% of them for GLP-1s. Another 2.5 crore pens of annual capacity is due by end-September, taking the total to about 7.5 crore. Management expects to beat its FY27 guide of 3.6 crore pens. The tension: the growth half rides on a few pharma partners' generic semaglutide launches, and the company does not disclose customer concentration. The shrinking half is the one with the longest history

Pondy Oxides — sold 25% less lead. Earned a record on every tonne. Q1 FY27: Standalone revenue Rs 931 cr, +56% YoY EBITDA Rs 56 cr, +30% PAT Rs 36 cr, +32% Lead volume: down 25% Lead EBITDA/tonne: Rs 21,595 — highest ever Value-added share of lead: 85%, from about 55% Copper volumes: more than 3x Copper EBITDA/tonne: Rs 48,488, +66% Copper cathode plant: 36,000 tpa, Phase 1 of 18,000 t by Dec 2026 FY27 capex: about Rs 175 cr Volume was given up on purpose to protect the mix. Bear line: management's own sustainable range is Rs 18,000–20,000 a tonne. The record quarter sits above the company's own guide, and blended EBITDA margin still slipped to 6.0% from 7.2%.

IKS Health — five clients bring 42.1% of revenue. The next five add 11.7%. Q1 FY27, from the investor presentation and the call: Revenue about Rs 893 cr, up 21% YoY Constant-currency growth: 12% EBITDA Rs 294 cr, 33% margin Top 5 clients: 42.1% of revenue Top 10 clients: 53.8% of revenue Do the subtraction. Clients six to ten together bring 11.7% — barely a quarter of what the top five bring. The comfort is tenure: top-five relationships average 7.41 years, top-ten 5.76 years. These are a small number of large US health systems that have stayed. The tension sits in the growth line. Of the 21 points of reported growth, 9 came from the rupee, not from clients. A business this concentrated, growing 12% in its own currency, is a different read from one growing 21%